Novo investors call for dealmaking and new drugs
Ozempic maker is under pressure to diversify as it prepares to face shareholders on Monday
Read the full story at Financial Times ↗
ImpactNotable 35/100
Why it mattersRule-based estimate: no strong signals; trust 9/10.
RegionsUnited Kingdom
Published3 h ago (Sun, 20 Sep 2026 04:00:11 GMT)
RetrievedSun, 20 Sep 2026 06:00:13 GMT via rss
ClassifiedSun, 20 Sep 2026 06:00:24 GMT by heuristic